FREQUENTLY ASKED QUESTIONS
Why is it important to treat GPP continuously?
Learn more by watching this video.
Watch expert Dr. Adam Friedman, Professor and Chair of Dermatology at George Washington University School of Medicine and Health Sciences, discuss treatment goals and the importance of continuous GPP treatment.
Please see Important Safety Information below.
Dr. Adam Friedman has been compensated for his time.
Why is it important to target the IL-36 pathway in GPP?
Learn more by watching this video.
Watch expert Dr. Adam Friedman, Professor and Chair of Dermatology at George Washington University School of Medicine and Health Sciences, explain the role of the IL-36 pathway in GPP and how SPEVIGO could help treat your patients with GPP.
Please see Important Safety Information below.
Dr. Adam Friedman has been compensated for his time.
When should I use SPEVIGO (SC) and SPEVIGO (IV)?
Learn more by watching this video.
Watch expert Dr. Raj Chovatiya, Associate Professor of Medicine at Northwestern University, discuss the differences between SPEVIGO formulations and provide guidance on when to use them.
Please see Important Safety Information below.
Dr. Raj Chovatiya has been compensated for his time.
How long should patients stay on SPEVIGO (SC)?
Learn more by watching this video.
Watch expert Dr. Raj Chovatiya, Associate Professor of Medicine at Northwestern University, clarify how treatment length with SPEVIGO (SC) could translate into continuous benefits for patients with GPP.
Please see Important Safety Information below.
Dr. Raj Chovatiya has been compensated for his time.
IL-36, interleukin-36; IV, intravenous; SC, subcutaneous.